2018/10/01 by Elihu H. Estey · 1 citation
Medicine · #Acute Myeloid Leukemia Research #Myeloproliferative Neoplasms: Diagnosis and Treatment #Hematopoietic Stem Cell Transplantation #Medicine #Myeloid leukemia #Internal medicine #Disease #Incidence (geometry) #Minimal residual disease #Complete remission #Risk stratification #Intensive care medicine #Myeloid #Oncology #Leukemia #Chemotherapy
paper · doi:10.1002/ajh.25214
openalex publication_date 2018/10/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason patients are not cured is resistance to treatment, often manifested as relapse from remission, rather than, even in older patients, TRM, whose incidence is decreasing. Knowledge of the pre-treatment mutation status of various genes has improved our ability to assign initial treatment and, of particular importance, knowledge of whether patients ostensibly in remission have measurable residual disease should influence subsequent management. Several new drugs have been approved by the FDA and we discuss their role in treatment.